Dendreon busts out of biotech with capacity boost

Dendreon say all three of its manufacturing plants should be online and shipping its prostate cancer vaccine by year's end. Provenge is the first vaccine approved for cancer treatment. The manufacturing ramp-up makes Dendreon "a biotech that's become a commercial company now," says Needham & Co. analyst Mark Monane. Sales of the drug were stymied by production constraints. But expansion at a New Jersey plant and  pending regulatory approvals for plants in California and Georgia should eliminate the problem. Story


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.